Безопасность и риск фармакотерапии (Feb 2018)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor

  • T. M. Bukatina,
  • A. S. Kazakov,
  • N. Yu. Velts,
  • M. A. Darmostukova,
  • K. E. Zatolochina,
  • R. N. Alyautdin,
  • V. P. Dobrynin,
  • B. K. Romanov

Journal volume & issue
Vol. 0, no. 4
pp. 23 – 26

Abstract

Read online

Inhibitors of the sodium-glucose cotransporter-2 SGLT2 is a new class of hypoglycemic drugs. This article presents the information on FDA reports (2013-2015) and AIS (May 2015 - February 2016) on the risk of new adverse reaction - ketoacidosis. Conjectural pathophysiological mechanisms of ADR associated with this class of drugs, which could lead to its development are presented.

Keywords